Response

Affiliations

¹ Liverpool Centre for Cardiovascular Science, University of Liverpool, and Liverpool Heart and Chest Hospital, Liverpool, United Kingdom; Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. Electronic address: gregory.lip@liverpool.ac.uk.
² Cardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
³ Uniformed Services University of the Health Sciences, F. Edward Hebert School of Medicine, Bethesda, MD.

Comment

Gregory Y H Lip et al. Chest. 2019 Jun.

. 2019 Jun;155(6):1307.

doi: 10.1016/j.chest.2019.02.329.

¹ Liverpool Centre for Cardiovascular Science, University of Liverpool, and Liverpool Heart and Chest Hospital, Liverpool, United Kingdom; Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. Electronic address: gregory.lip@liverpool.ac.uk.
² Cardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
³ Uniformed Services University of the Health Sciences, F. Edward Hebert School of Medicine, Bethesda, MD.

No abstract available

Comment on

Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report.
Lip GYH, Banerjee A, Boriani G, Chiang CE, Fargo R, Freedman B, Lane DA, Ruff CT, Turakhia M, Werring D, Patel S, Moores L. Lip GYH, et al. Chest. 2018 Nov;154(5):1121-1201. doi: 10.1016/j.chest.2018.07.040. Epub 2018 Aug 22. Chest. 2018. PMID: 30144419
The Use of Rivaroxaban in Patients With Atrial Fibrillation Receiving Hemodialysis-Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report.
Moore KT. Moore KT. Chest. 2019 Jun;155(6):1306-1307. doi: 10.1016/j.chest.2019.02.323. Chest. 2019. PMID: 31174647 No abstract available.